Next Day Disclosure Return
Filed with HKEX · Stock code 1672 · · 7 pages · English
Earlier from Ascletis Pharma
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026
- Interim Report 2026
- Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
- Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
Later from Ascletis Pharma
- Voluntary announcement - ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline for the treatment of obesity
- Voluntary announcement - ascletis' strategic partner sagimet announces first patient dosed in phase iii U.S. clinical trial of denifanstat (ASC40) for moderate to severe acne
Follow Ascletis Pharma into a list and get an email when it puts out news.
Follow Ascletis Pharma